Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN71,8671,941,60
Msft-0,74
Nokia5,065,1190,22
IBM0,79
Mercedes-Benz Group AG60,5960,610,00
PFE-3,32
12.08.2022 1:38:39
Indexy online
AD Index online
select
AD Index online
 

  • 11.08.2022 22:00:00
Biomarin Pharma (BMRN.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
95,07 -0,97 -0,93 1 221 993
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 12.08.2022
Popis společnosti
Obecné informace
Název společnostiBiomarin Pharmaceutical Inc
TickerBMRN
Kmenové akcie:Ordinary Shares
RICBMRN.O
ISIN-
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.06.2022
Počet zaměstnanců k 31.12.2021 3 045
Akcie v oběhu k 30.06.2022 185 452 454
MěnaUSD
Kontaktní informace
Ulice105 Digital Dr
MěstoNOVATO
PSČ94949-8703
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon14 155 066 700
Fax14153827889

Business Summary: BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Biomarin Pharmaceutical Inc revenues increased 7% to $1.05B. Net income increased from $30.3M to $148.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Gain on sale of nonfinancial assets increase from $0K to $108M (income), Amortisation of Intangibles decrease of 50% to $15.6M (expense).
Odvětvová klasifikace
TRBC2012Biopharmaceuticals
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 12.08.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerJean-Jacques Bienaime68
Chief Financial Officer, Executive Vice President - FinanceBrian Mueller4829.06.2020
President - Worldwide Research and DevelopmentHenry Fuchs6402.03.2009
Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical OfficerC. Greg Guyer6004.05.202004.05.2020
Executive Vice President, General Counsel, SecretaryG. Eric Davis51
Executive Vice President, Chief Commercial OfficerJeff Ajer59
Senior Vice President, Chief Marketing OfficerHumaira Serajuddin-05.05.202205.05.2022
Group Vice President, Chief Accounting OfficerErin Burkhart4302.05.202202.05.2022